Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
Martina Sanlorenzo(University of California, San Francisco), Susana Ortiz‐Urda(University of California, San Francisco), Matthew A. Gubens(University of California, San Francisco), Klemens Rappersberger(Rudolfinerhaus Hospital), Pietro Quaglino(Department of Medical Sciences), Alain P. Algazi(University of California, San Francisco), Igor Vujic(Cancer Research Center), Sara Alcántara Luna(University of California, San Francisco), Kevin Lin(Cancer Research Center), Adil Daud(Memorial Sloan Kettering Cancer Center)
Cited by 452
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
|Nature Medicine|2018|1k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
|Journal of the National Comprehensive Cancer Network|2021|1k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2019|1k